RARE Logo

Ultragenyx Pharmaceutical Inc. (RARE) 

NASDAQ
Market Cap
$4.62B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
689 of 776
Rank in Industry
375 of 433

Largest Insider Buys in Sector

RARE Stock Price History Chart

RARE Stock Performance

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with …

Insider Activity of Ultragenyx Pharmaceutical Inc.

Over the last 12 months, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $7.88M worth of Ultragenyx Pharmaceutical Inc. stock.

On average, over the past 5 years, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $13.14M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $218,150 was made by KAKKIS EMIL D (President & CEO) on 2019‑09‑11.

List of Insider Buy and Sell Transactions, Ultragenyx Pharmaceutical Inc.

2024-10-10SaleChief Financial Officer
7,465
0.0077%
$52.76$393,853+1.69%
2024-09-03SalePresident & CEO
20,000
0.0218%
$55.85$1.12M+0.02%
2024-09-03SaleSVP, Chief Accounting Officer
91
<0.0001%
$56.19$5,113+0.02%
2024-08-06SalePresident & CEO
20,000
0.0223%
$50.17$1M+12.04%
2024-07-02Saledirector
584
0.0007%
$40.98$23,9320.00%
2024-06-12SaleEVP and Chief Legal Officer
9,806
0.0128%
$45.00$441,270+20.47%
2024-06-10Saledirector
1,737
0.002%
$41.10$71,391+27.85%
2024-05-02SaleEVP and Chief Medical Officer
354
0.0004%
$43.66$15,456+15.81%
2024-04-18SaleEVP and Chief Medical Officer
142
0.0002%
$44.10$6,262+4.31%
2024-03-11SaleCBO & EVP
11,509
0.0144%
$49.93$574,644-3.58%
2024-03-07Saledirector
12,195
0.0147%
$50.88$620,443-7.81%
2024-03-01SaleCBO & EVP
1,011
0.0012%
$53.76$54,351-12.52%
2024-03-01SaleSee Remarks
4,173
0.0051%
$53.76$224,340-12.52%
2024-03-01SaleEVP and Chief Legal Officer
3,756
0.0046%
$53.76$201,923-12.52%
2024-03-01SaleEVP & Chief Commercial Officer
4,768
0.0058%
$53.76$256,328-12.52%
2024-03-01SaleEVP and Chief Medical Officer
1,238
0.0015%
$53.76$66,555-12.52%
2024-03-01SaleSVP, Chief Accounting Officer
341
0.0004%
$53.76$18,332-12.52%
2024-02-07SalePresident & CEO
30,000
0.0366%
$45.00$1.35M+5.23%
2023-12-29SalePresident & CEO
30,000
0.0365%
$47.87$1.44M-2.25%
2023-10-23SaleCBO & EVP
39,878
0.057%
$32.78$1.31M+41.95%

Insider Historical Profitability

12.34%
KAKKIS EMIL DPresident & CEO
2223985
2.413%
$50.08223+13.31%
Kassberg Thomas RichardCBO & EVP
252823
0.2743%
$50.08125
Fust Matthew Kdirector
14860
0.0161%
$50.0816
FMR LLC10 percent owner
3260240
3.5374%
$50.0810+10.41%
Sharp ShaliniEVP, Finance
97812
0.1061%
$50.08128

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$406.2M9.38.7M+0.31%+$1.24M0.01
RTW Investments, LP$330.9M7.587.09M+2.9%+$9.34M4.96
BlackRock$244.46M5.65.24M-0.05%-$124,288.780.01
Wellington Management Company$191.33M4.384.1M-7.18%-$14.8M0.03
Sands Capital$180.2M4.133.86M-6.28%-$12.07M0.5
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.